Targeting complete response with upfront bortezomib consolidation versus observation after the achievement of complete response following autologous transplantation for multiple myeloma (TUBA study)

Complete response (CR) after treatment for multiple myeloma is associated with superior progression‐free survival (PFS). Multiple myeloma patients were prospectively recruited for induction treatment with bortezomib and dexamethasone (BD) followed by autologous hematopoietic cell transplantation (au...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Hematological oncology 2018-02, Vol.36 (1), p.202-209
Hauptverfasser:	Nakasone, Hideki, Terasako‐Saito, Kiriko, Hirano, Teiichi, Wake, Atsushi, Shimizu, Seiichi, Kurita, Naoki, Yamazaki, Etsuko, Usuki, Kensuke, Akazawa, Kohei, Kanda, Junya, Minauchi, Koichiro, Yamamoto, Go, Tanimoto, Shiori, Kamoshita, Masaharu, Yokoyama, Yasuhisa, Miyaoka, Etsuo, Ota, Shuichi, Kako, Shinichi, Izutsu, Koji, Kanda, Yoshinobu
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Antineoplastic Combined Chemotherapy Protocols - pharmacology Antineoplastic Combined Chemotherapy Protocols - therapeutic use Autografts autologous hematopoietic cell transplantation Bortezomib Bortezomib - therapeutic use Consolidation Consolidation Chemotherapy Dexamethasone Female Humans Inhibitor drugs Male Middle Aged Multiple myeloma Multiple Myeloma - surgery Multiple Myeloma - therapy Patients Stem cell transplantation Survival Targeted cancer therapy targeting complete response Therapy Transplantation Transplantation, Autologous Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!